2020 American Transplant Congress
A Multicenter Analysis of the Proportion and Pattern of Unexplained HLA Antibodies in Kidney Recipients without a History of Sensitization
*Purpose: Previous studies report a high prevalence of unexplained antibody reactivities on the single antigen bead (SAB) test. In a contemporary multicenter cohort of non-sensitized…2020 American Transplant Congress
Donor-Specific Antibody Test as a Screening Tool for Stable Long-Term Kidney Transplant Recipients
1Department of Nephrology, Madison, WI, 2Department of Surgery, Madison, WI
*Purpose: Donor-specific antibody (DSA) is an established biomarker predicting antibody mediated rejection (AMR), but at substantial cost. The utility of DSA test as a screening…2020 American Transplant Congress
Crosstalk between TLR4 and HLA Class I Mediates P-Selectin Expression and Monocyte Capture to Endothelial Cells
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
*Purpose: Transplant recipients developing donor specific HLA antibodies (DSA) are at risk for acute and chronic antibody-mediated rejection (AMR). DSA contribute to the process of…2020 American Transplant Congress
Effects of Donor Specific Antibodies in Intestinal/Multivisceral Transplant Recipients
1University Health System, San Antonio, TX, 2Nebraska Medicine, Omaha, NE
*Purpose: Evaluate the effects of donor specific antibodies (DSAs) on outcomes in post-intestinal/multivisceral (MV) transplant patients and describe the presentation of DSAs post-transplant.*Methods: This single-center…2020 American Transplant Congress
Is the Epitope Mismatch Load Enough to Identify HLA-DQ Mismatches with a Low Risk for De Novo DSA Development?
*Purpose: The development of de novo donor-specific anti-HLA antibodies (dnDSA) remains a major risk factor for poor long-term kidney allograft outcomes. In particular, anti-HLA-DQ dnDSAs,…2020 American Transplant Congress
Association between Longer Hospitalization and Development of De Novo Donor Specific Antibody in Simultaneous Liver-Kidney Transplant Recipients
*Purpose: De novo Donor Specific Antibodies (DSA) are considered a risk factor for worsening kidney allograft outcomes in recipients after simultaneous liver-kidney transplantation (SLK). No…2020 American Transplant Congress
Analysis of 1000 Protocol Kidney Biopsies: Complications, Benefits, and Predictive Potential of Prior Sensitization
*Purpose: Protocol biopsy of kidney transplants can allow for early recognition of treatable findings, both immunologic and non-immunologic. This comes with the risk of biopsy…2020 American Transplant Congress
HLA Specific Antibody Levels after EDTA Treatment in CDC Crossmatch Positive and Negative Sera with Known Donor-Specific Antibodies
*Purpose: Ethylenediaminetetraacetic acid (EDTA) treatment of serum samples overcomes the prozone effect that may interfere with solid phase HLA specific antibody analyses. In patients with…2020 American Transplant Congress
Simultaneous Liver and Kidney Transplantation—The Lack of Influence of Pre-Formed DSA
Recanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, NY
*Purpose: It is known that renal transplant recipients with preformed donor specific antibodies (DSA) have poorer outcomes associated with episodes of acute rejection (AR) and…2020 American Transplant Congress
Belatacept Provides Superior Inhibition of Donor Specific Antibody Formation in Kidney Transplant Recipients with Acute Rejection
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: The factors responsible for chronic renal allograft dysfunction and premature graft loss are incompletely understood and likely multifactorial. Immunologic injury partially attributable to the…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 47
- Next Page »